326 related articles for article (PubMed ID: 26811660)
1. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
2. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
4. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
5. Role of p-21-activated kinases in cancer progression.
King H; Nicholas NS; Wells CM
Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727
[TBL] [Abstract][Full Text] [Related]
6. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
7. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
8. Rho family GTPase signaling through type II p21-activated kinases.
Chetty AK; Ha BH; Boggon TJ
Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
[TBL] [Abstract][Full Text] [Related]
9. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Wu A; Jiang X
Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
[TBL] [Abstract][Full Text] [Related]
10. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
11. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.
Yi C; Maksimoska J; Marmorstein R; Kissil JL
Biochem Pharmacol; 2010 Sep; 80(5):683-9. PubMed ID: 20302846
[TBL] [Abstract][Full Text] [Related]
12. p21-activated kinase 1: PAK'ed with potential.
Ong CC; Jubb AM; Zhou W; Haverty PM; Harris AL; Belvin M; Friedman LS; Koeppen H; Hoeflich KP
Oncotarget; 2011 Jun; 2(6):491-6. PubMed ID: 21653999
[TBL] [Abstract][Full Text] [Related]
13. Targeting group II PAKs in cancer and metastasis.
Eswaran J; Soundararajan M; Knapp S
Cancer Metastasis Rev; 2009 Jun; 28(1-2):209-17. PubMed ID: 19160016
[TBL] [Abstract][Full Text] [Related]
14. PAK as a therapeutic target in gastric cancer.
Li X; Liu F; Li F
Expert Opin Ther Targets; 2010 Apr; 14(4):419-33. PubMed ID: 20146633
[TBL] [Abstract][Full Text] [Related]
15. Role of p21-activated kinases in cardiovascular development and function.
Kelly ML; Astsaturov A; Chernoff J
Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
17. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
[TBL] [Abstract][Full Text] [Related]
19. Tracing PAKs from GI inflammation to cancer.
Dammann K; Khare V; Gasche C
Gut; 2014 Jul; 63(7):1173-84. PubMed ID: 24811999
[TBL] [Abstract][Full Text] [Related]
20. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
